NewsRoom Articles - Page 134 of 214

ThursdayNov 11, 2021 10:41 am

How Virtual Monitoring Can Transform Patients’ Care

The advancement of innovations and technology in different sectors has made it easier to access information on almost anything you can think of. The healthcare sector in particular has experienced various changes, with medical technology reshaping healthcare, leading to the evolution of patient care and management. These advances in healthcare technology have made it possible for patients to connect with their physicians at any time, which has redefined the patient-physician connection. The role of remote monitoring in healthcare has also been highlighted with the advancement of medical technology, especially in the early detection and treatment of cardiovascular ailments. Today, we…

WednesdayNov 10, 2021 11:56 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) Files International Patent Application for Treating Neurodegenerative Diseases Using a New Rare Cannabinoid

InMed Pharmaceuticals has filed an international patent application that specifies a rare cannabinoid that may inhibit or slow the progression of neurodegenerative disease and potentially enhance the neuronal function With neurogenerative diseases affecting millions worldwide and the cost of treating patients expected to rise in the future, finding treatments and cures is a matter of increasing urgency InMed’s patent application is a promising start, expanding the company’s patent portfolio, which currently includes twelve patent families InMed Pharmaceuticals (NASDAQ: INM), a global leader in the manufacturing and pharmaceutical development of rare cannabinoids, recently filed a Patent Cooperation Treaty (“PCT”) application, titled…

WednesdayNov 10, 2021 9:30 am

Study Finds That Insomnia Worsens Quality of Life in Adults with MDD

Major depressive disorder (“MDD”) is a medical condition that affects an individual’s behavior, mood and physical function, including sleep and appetite. This condition is sometimes referred to as clinical depression and is among the most common mental health conditions in the United States. Insomnia is a sleep disorder that makes it hard for an individual to stay asleep, fall asleep or wake up too early. This disorder drains an individual’s mood and energy level, which affects different aspects of their lives. A new study has found that higher insomnia severity is linked to poorer quality of life and worse clinical…

TuesdayNov 09, 2021 8:30 am

Lifestyle Changes That May Help Stop Binge Eating

Eating disorders such as anorexia and binge eating are serious illnesses characterized by damaging and complex relationships with body image, exercise, food and eating. Individuals suffering from binge eating disorder usually experience recurrent episodes, which involve the consumption of huge amounts of food, feeling they have lost control and experiencing feelings of shame or guilt after the binge. This disorder can cause obesity if it remains untreated, which in turn leads to other severe health issues, including gallbladder disease and type 2 diabetes. Binge eating disorder is usually managed with medication, nutritional counseling and psychotherapy. In addition to this, lifestyle…

MondayNov 08, 2021 9:00 am

Study Finds High Triglyceride Levels May Be Linked to Obstructive Sleep Apnea

A new study has discovered a link between triglycerides and obstructive sleep apnea ("OSA"). Triglycerides are a type of lipid in the blood that gives energy to an individual’s body. High triglyceride levels raise an individual’s risk of pancreatitis, strokes and heart attack. On the other hand, obstructive sleep apnea is a sleep disorder that causes an individual’s airway to close while they sleep, which prevents the lungs from oxygenating the blood sufficiently. This common sleep disorder has many symptoms, which include choking, gasping, loud snoring, drowsiness, morning headaches, poor school and job performance, hyperactivity in young children and waking…

FridayNov 05, 2021 10:51 am

German Cannabis Market Expected to Liberalize Post Election, RYAH Group Inc. (CSE: RYAH) Enters Germany Via Observational Study

German Social Democrat-led coalition expected to liberalize medical cannabis market Analysts predict over one million medical cannabis patients in Germany by 2024, market estimated to reach $8.9 billion by 2028 RYAH entered German market via observational study with Four 20 Pharma GmbH RYAH provides IoT product ecosystem of volume-control devices, medicine-carrying components, mobile applications RYAH ecosystem offers reliable way for researchers and clinicians to develop well-controlled research environments Germany’s recent 2021 election is expected to result in a new political environment via a coalition containing cannabis-positive political factions that aim to liberalize the country’s plant-based medicine market (https://ibn.fm/t1Zgg). RYAH Group…

FridayNov 05, 2021 9:30 am

Climate Change Takes Heavy Toll on Mental Health

As the 26th Climate Change Conference (CoP26) gets underway, a number of experts are calling attention to the detrimental effects that climate change has on mental health. These experts say this component isn’t being given as much attention as it deserves by policymakers. According to a recent report released by the World Health Organization, climate change is the most significant threat to health that humanity faces. Already, the world is witnessing loss of life due to extreme heat events, waterborne diseases, zoonotic diseases, and malnutrition among other such climate-related causes of mortality. While the climate change threats above aren’t receiving…

FridayNov 05, 2021 7:36 am

Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Validates its AI-Driven Drug Discovery Program with Successful Synthesis of Novel Tryptamine; Confirms Participation in the Wonderland: Miami Psychedelic Medicine Business Event

Mydecine just announced the successful synthesis of a novel psilocin analogue, a tryptamine The achievement adds to the company’s library of patent-pending tryptamines for medical use and therapy, and is seen as verifying the value of Mydecine’s AI-driven drug discovery program Mydecine has also confirmed its participation in the Wonderland: Miami psychedelic medicine event scheduled for November 8-9, 2021, where the company will share its recent research advancements and goals going forward Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) just announced the successful synthesis of a novel psilocin analogue, a tryptamine, that has proven to have improved pharmaceutical properties (https://ibn.fm/I2lX7).…

ThursdayNov 04, 2021 12:50 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Marks Another Significant Milestone with IND Application for Fibromyalgia Phase 2a Clinical Trial

Tryp just filed an IND with the FDA for its TRP-8802 clinical candidate for its Phase 2a clinical trial The trial is set to commence in 2022, subject to a favorable review by the FDA The study will be conducted in collaboration with the University of Michigan and will aim at evaluating the safety and clinical utility of psilocybin for fibromyalgia Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) just announced its submission of an Investigational New Drug (“IND”) application to the United States Food and Drug Administration (“FDA”) for its TRP-88802 clinical candidate. This application follows the commencement of Tryp’s Phase…

ThursdayNov 04, 2021 12:33 pm

Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) Growth Strategy Moves Forward with Awakn Life Sciences (NEO: AWKN) (OTCQB: AWKNF) Partnership for Ketamine-Assisted Psychotherapy Distribution

The distribution component unlocks a new revenue source for the company, helping drive future growth MINDCURE’s platform was built as a digital tool and distribution platform, and has already been used for deployment and distribution of ketamine for depression and pain Digital therapeutics market is projected to reach USD $13.1 billion by 2026 from USD $3.4 billion in 2021 at a CAGR of 31.4 %, a substantial increase primarily driven by the COVID-19 pandemic and the stressors associated with it MINDCURE’s target areas and value proposition list numerous benefits for therapists, patients, payers, and drug and protocol developers, through the…